The Ravetch lab is characterizing the immune complex-vaccination platform by targeting specific FcyR pathways critical for inducing potent humoral and cellular immunity. The ultimate goal of this work addresses the global need for seasonal vaccination against influenza by creating a “universal” influenza vaccine.
By binding to receptors on immune cells, antibodies mediate immune responses ranging from neutralizing pathogens to suppressing inflammation. The Ravetch lab investigates the complex biology of these antibody-Fc receptor interactions, and their roles in normal immune function and disease. These studies are providing novel approaches to treating infectious and inflammatory diseases, as well as cancer.
